Europe Genomics Market Report: Market Size & Forecast 2026

The European genomics market includes a broad ecosystem of sequencing platforms, bioinformatics tools, laboratory services, and clinical diagnostics based on genomic analysis. The market spans research institutions, hospitals, pharmaceutical companies, and direct-to-consumer genetic testing providers across the European Union and non-EU countries including the United Kingdom and Switzerland. At approximately $7.04 billion in 2025, the sector represents one of the world's largest regional genomics markets, supported by strong academic research infrastructure and progressive regulatory frameworks for genomic medicine.

• •Market encompasses sequencing technologies, bioinformatics software, genomic services, and clinical diagnostics
• •Serves diverse end-users including hospitals, research institutions, pharmaceutical firms, and consumers
• •Supported by established academic infrastructure and regulatory frameworks across EU and non-EU European countries

Precision medicine initiatives and the integration of genomics into routine clinical practice are primary catalysts for market expansion. National healthcare systems in countries such as Germany, France, and the United Kingdom are increasingly incorporating genomic testing into cancer care, rare disease diagnosis, and pharmacogenomics programs. The ongoing reduction in whole-genome sequencing costs, combined with advances in artificial intelligence-driven genomic analysis, is making large-scale genomic screening economically viable.

• •Integration of genomics into clinical care for cancer, rare diseases, and pharmacogenomics
• •Rising government and institutional investment in precision medicine programs
• •Declining sequencing costs and advancement in AI-powered genomic analysis tools

The market is typically segmented by technology type, including next-generation sequencing, polymerase chain reaction, microarrays, and genome editing technologies, as well as by end-use applications spanning research, clinical diagnostics, and agriculture. Western Europe leads in market value, with Germany representing a significant share at an estimated $2.77 billion in 2025. The United Kingdom, France, and Germany collectively account for a substantial portion of European genomics activity, while Eastern European markets are emerging as growth areas.

• •Germany estimated at $2.77 billion in 2025, forecast to reach $4.24 billion by 2030
• •UK, France, and Germany lead regional genomics activity
• •Eastern European markets showing emerging growth potential

What are the recent trends and outlook?

The market is expected to maintain double-digit growth through the coming decade, driven by expanding clinical adoption of genomic medicine and increasing population-scale genomic screening programs. Long-read sequencing technologies, single-cell genomics, and spatial transcriptomics are emerging as high-growth segments. Regulatory harmonization efforts across the European Union, including data governance frameworks for genomic information, are shaping market development.

• •Long-read sequencing, single-cell genomics, and spatial transcriptomics emerging as key technology segments
• •Population-scale genomic screening initiatives expanding across European countries
• •EU data governance regulations influencing genomic data sharing and market operations